Cirino Giuseppe, Fusco Ferdinando, Imbimbo Ciro, Mirone Vincenzo
Dipartimento di Farmacologia Sperimentale, Via Domenico Montesano 49, 8031 Napoli, Italy.
Pharmacol Ther. 2006 Aug;111(2):400-23. doi: 10.1016/j.pharmthera.2005.10.011. Epub 2006 Jan 26.
Erectile dysfunction (ED) is defined as the consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual activity (2nd International Consultation on Sexual Dysfunction-Paris, June 28th-July 1st, 2003). Following the discovery and introduction of sildenafil, research on the mechanisms underlying penile erection has had an enormous boost and many preclinical and clinical papers have been published in the last 5 years. This review is structured in order to give the reader an overview of the clinical and preclinical data available on the peripheral regulation of and the mediators involved in human penile erection. The most widely accepted risk factors for ED are discussed. The article is focused on human data, and the safety and effectiveness of the 3 commercially available Phosphodiesterase-5 (PDE5) inhibitors used to treat ED are also discussed.
勃起功能障碍(ED)被定义为男性持续或反复无法获得和/或维持足以进行性活动的阴茎勃起(2003年6月28日至7月1日在巴黎举行的第二届国际性功能障碍咨询会议)。西地那非被发现和应用后,对阴茎勃起潜在机制的研究得到了极大推动,在过去5年里发表了许多临床前和临床研究论文。本综述旨在让读者全面了解有关人类阴茎勃起的外周调节及相关介质的临床和临床前数据。文中讨论了ED最广泛认可的风险因素。本文聚焦于人类数据,还讨论了用于治疗ED的3种市售磷酸二酯酶5(PDE5)抑制剂的安全性和有效性。